Frequency Therapeutics Q2 EPS $(0.30) Beats $(0.35) Estimate
Portfolio Pulse from Benzinga Newsdesk
Frequency Therapeutics reported Q2 losses of $(0.30) per share, beating the analyst consensus estimate of $(0.35) by 14.29%. This represents a 50.82% increase over losses from the same period last year.
August 10, 2023 | 8:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Frequency Therapeutics' Q2 losses were less than expected, indicating a potential improvement in the company's financial performance.
Frequency Therapeutics reported lower than expected losses for Q2, which is a positive sign for the company's financial health. This could lead to increased investor confidence and potentially a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100